Clearside Biomedical secures Health Canada approval for Xipere, while exploring strategic options to enhance its suprachoroidal delivery platform and pipeline. In recent news from biopharmaceutical ...
ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Clearside’s patent protected, proprietary suprachoroidal space (SCS®) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs. The ...
Clearside developed and gained approval for its first product, XIPERE ® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial ...
Clearside Biomedical, Inc. (NASDAQ:CLSD – Free Report) – HC Wainwright upped their Q1 2025 earnings estimates for Clearside Biomedical in a note issued to investors on Monday, March 31st. HC ...
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday. A number of other ...
ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to ...
Clearside Biomedical, Inc. announced the approval of Arctic Vision's ARCATUS® (known as XIPERE® in the U.S.) by the Therapeutic Goods Administration in Australia and the Health Sciences Authority in ...
ALPHARETTA, Ga., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results